| Pair Name | Decursin, Doxorubicin | ||
| Phytochemical Name | Decursin (PubChem CID: 442126 ) | ||
| Anticancer drug Name | Doxorubicin (PubChem CID: 31703 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Decursin, Doxorubicin | |||
| Disease Info | [ICD-11: 2A83] | Multiple myeloma | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | BIRC5 | hsa332 |
| Up-regulation | Activity | CASP3 | hsa836 | |
| Up-regulation | Activity | CASP9 | hsa842 | |
| Down-regulation | Expression | CCND1 | hsa595 | |
| Down-regulation | Phosphorylation | JAK2 | hsa3717 | |
| Up-regulation | Phosphorylation | MAPK1 | hsa5594 | |
| Down-regulation | Phosphorylation | MTOR | hsa2475 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Up-regulation | Activity | PTPN11 | hsa5781 | |
| Down-regulation | Phosphorylation | RPS6KB1 | hsa6198 | |
| Down-regulation | Phosphorylation | SRC | hsa6714 | |
| Down-regulation | Phosphorylation | STAT3 | hsa6774 | |
| In Vitro Model | U266B1 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_0566 |
| RPMI-8226 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_0014 | |
| MM.1S | Plasma cell myeloma | Homo sapiens (Human) | CVCL_8792 | |
| Result | The combination treatment of decursin and doxorubicin can enhance apoptotic activity via mTOR and/or STAT3 signaling pathway in multiple myeloma cells. | |||
| Pair Name | Decursin, Doxorubicin | |||
| Disease Info | [ICD-11: 2C73] | Ovarian cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | ABCB1 | hsa5243 |
| Up-regulation | Activity | CASP3 | hsa836 | |
| Up-regulation | Activity | CASP8 | hsa841 | |
| Up-regulation | Activity | CASP9 | hsa842 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| In Vitro Model | NCI-ADR-RES | High grade ovarian serous adenocarcinoma | Homo sapiens (Human) | CVCL_1452 |
| Result | AGN would be a potentially novel treatment option for multidrug-resistant tumors by sensitizing to anticancer agents. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Decursin and Doxorubicin Are in Synergy for the Induction of Apoptosis via STAT3 and/or mTOR Pathways in Human Multiple Myeloma Cells. Evid Based Complement Alternat Med. 2013;2013:506324. doi: 10.1155/2013/506324. | Click |
| 2 | Decursin in Angelica gigas Nakai (AGN) Enhances Doxorubicin Chemosensitivity in NCI/ADR-RES Ovarian Cancer Cells via Inhibition of P-glycoprotein Expression. Phytother Res. 2016 Dec;30(12):2020-2026. doi: 10.1002/ptr.5708. | Click |
